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Cancer cell CCR2 orchestrates suppression of the
adaptive immune response
Miriam R. Fein1,2*, Xue-Yan He1*, Ana S. Almeida1, Emilis Bruzˇas1,3, Arnaud Pommier1, Ran Yan1,3, Ana¨ıs Eberhardt1,4, Douglas T. Fearon1,5,6,
Linda Van Aelst1, John Erby Wilkinson7, Camila O. dos Santos1, and Mikala Egeblad1
C-C chemokine receptor type 2 (CCR2) is expressed on monocytes and facilitates their recruitment to tumors. Though breast
cancer cells also express CCR2, its functions in these cells are unclear. We found that Ccr2 deletion in cancer cells led to reduced
tumor growth and approximately twofold longer survival in an orthotopic, isograft breast cancer mouse model. Deletion of
Ccr2 in cancer cells resulted in multiple alterations associated with better immune control: increased infiltration and
activation of cytotoxic T lymphocytes (CTLs) and CD103+ cross-presenting dendritic cells (DCs), as well as up-regulation of MHC
class I and down-regulation of checkpoint regulator PD-L1 on the cancer cells. Pharmacological or genetic targeting of CCR2
increased cancer cell sensitivity to CTLs and enabled the cancer cells to induce DC maturation toward the CD103+ subtype.
Consistently, Ccr2−/− cancer cells did not induce immune suppression in Batf3−/− mice lacking CD103+ DCs. Our results establish
that CCR2 signaling in cancer cells can orchestrate suppression of the immune response.
Introduction
Tumors escape immune control via multiple mechanisms (Dunn
et al., 2002, 2004). These mechanisms include cancer cell–
intrinsic changes that alter how the cancer cell is recognized by
the immune system and extrinsic changes that suppress im-
mune cell activities. For example, cancer cells can intrinsically
decrease the surface expression of MHC class I, making them
effectively invisible to cytotoxic T lymphocytes (CTLs; Garrido
et al., 2016). Moreover, cancer cells can up-regulate programmed
cell death ligand 1 (PD-L1/B7-H1), which binds the PD-1 receptor
on activated T cells, resulting in T cell anergy, ultimately pro-
tecting cancer cells against T cell–mediated killing (Chen et al.,
2016a). Extrinsic mechanisms include the down-regulation of
costimulatorymolecules (e.g., CD86) on antigen-presenting cells;
the secretion of cytokines that directly inhibit CTLs; and the
recruitment of regulatory T cells and myeloid-derived suppres-
sor cells (MDSCs; Igney and Krammer, 2002). In contrast, infil-
tration of CD103+ dendritic cells (DCs) in mice, phenotypically
similar to CD141+ DCs in humans (Hildner et al., 2008), has
emerged as a mechanism by which tumors may be kept under
immune control. CD103+ DCs are highly efficient at acquiring
and processing exogenous antigens, which they directly pre-
sent on MHC class I molecules to CD8+ CTLs. Even a modest
accumulation of CD103+ DCs in tumors has been associated
with improved immune-mediated tumor control (Broz et al.,
2014; Roberts et al., 2016).
Chemokine receptors mediate the recruitment of immune
cells to sites of inflammation and to tumors. C-C chemokine
receptor type 2 (CCR2) is expressed by several bone marrow–
derived cell types (including inflammatory monocytes, myeloid
precursor cells, and immature DCs), as well as B and T lym-
phocytes (Lim et al., 2016). CCR2-expressing cells are recruited
to sites of inflammation primarily by C-C chemokine ligand
2 (CCL2; Deshmane et al., 2009), although other CCL family
members also can activate CCR2. Chemotherapy treatment pro-
motes CCR2-dependent infiltration of tumor-promoting myeloid
cells to murine mammary tumors (Nakasone et al., 2012), and
CCL2/CCR2–mediated recruitment of CCR2+ inflammatory mon-
ocytes to the lung has been shown to promote breast cancer ex-
travasation and metastasis in mouse models (Qian et al., 2011).
Furthermore, elevated levels of CCL2 in tumors and in serum are
associated with advanced disease and poor prognosis in breast
carcinoma patients (Lebrecht et al., 2004, 2001; Soria and Ben-
Baruch, 2008). These findings have sparked interest in targeting
the CCR2 pathway to modulate the innate immune response for
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therapeutic benefit in cancer. However, CCR2 is also expressed
by breast cancer cells, and activation of CCR2 by CCL2 can in-
duce cancer cell migration and survival through Smad3-, p42/
44MAPK–, and Rho guanosine triphosphatase–mediated sig-
naling (Fang et al., 2012). In vivo, the potential roles of CCR2
signaling in cancer cells have not been well investigated, largely
because they were thought to be minor compared with the roles
of CCR2 in myeloid cells.
In this study, we report that CCR2 signaling in cancer cells
plays a surprisingly major role in regulating the immune re-
sponse to murine breast tumors. We show that CCR2 in cancer
cells supports immune escape by inhibiting CD103+ DC infil-
tration and maturation and by suppressing CTL activity. CCR2
expression on cancer cells represents a previously uncharacterized
mechanism for immune suppression. Thus, our data support
the notion that the CCL2/CCR2 axis is an important immune
modulatory pathway in cancer, used by both immune cells and
cancer cells to orchestrate immune suppression.
Results
CCR2 in cancer cells promotes primary tumor growth in an
orthotopic, isograft breast cancer mouse model
To investigate the potential effects of CCR2 on breast tumor
growth and metastasis, we crossed Ccr2−/− mice (Boring et al.,
1997) with mouse mammary tumor virus–polyoma middle T
(MMTV-PyMT) mice, a model of luminal B breast cancer (Guy
et al., 1992; Lin et al., 2003). The Ccr2 genotype did not influence
normal mammary gland development (Fig. S1 A) or tumor onset
(Fig. 1 A); however, loss of even one allele of Ccr2 significantly
reduced tumor growth rates (Fig. 1 B). Consistently, survival
time was significantly longer for the MMTV-PyMT;Ccr2−/− and
MMTV-PyMT;Ccr2+/− mice compared with that of the MMTV-
PyMT;Ccr2+/+ mice (Fig. 1 C). In addition, we noted that the tu-
mors of MMTV-PyMT;Ccr2−/− and MMTV-PyMT;Ccr2+/− mice
were more cystic, with reduced solid areas, than those of
MMTV-PyMT;Ccr2+/+ mice (Fig. S1, B and C).
The importance of CCR2 signaling for monocyte recruitment
is well understood, but CCR2 is also expressed by human breast
cancer cells (Fang et al., 2012). In accordance with this report,
we detected Ccr2 mRNA and CCR2 protein in the cancer cells of
the tumors developing in MMTV-PyMT;Ccr2+/+ mice (Fig. 1, D
and E), and using RNA fluorescence in situ hybridization (FISH),
we demonstrated that Ccr2mRNA is expressed by Krt18-positive
breast cancer cells (Fig. S1 D). To determine the relative con-
tributions of cancer cell versus host CCR2 to tumor growth, we
isolated primary cancer cells (purity >90%; Fig. S1 E) from
MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2−/− mice and trans-
planted them orthotopically to mammary glands of either Ccr2+/+
or Ccr2−/− syngeneic hostmice (Fig. 1 F). Loss of Ccr2 in the host did
not alter tumor growth, consistent with our previous report
(Nakasone et al., 2012). However, loss of Ccr2 in cancer cells sig-
nificantly reduced tumor growth rates, leading to approximately
twofold longer survival (Fig. 1, G and H). Ccr2 mRNA levels of
Ccr2+/− cancer cells were lower than those of Ccr2+/+ cancer
cells (Fig. S1 F), and tumors derived from Ccr2+/− cancer cells
exhibited the same slow growth as tumors derived from Ccr2−/−
cancer cells (Fig. S1 G). This result suggests that a threshold level
of CCR2 expression in MMTV-PyMT cancer cells regulates tu-
mor growth.
CCR2+ inflammatory monocytes can promote breast cancer
metastasis (Müller et al., 2001; Qian et al., 2011). The overall
metastatic burden in the lung—the primary site of metastasis in
the MMTV-PyMT model—was, however, very variable in
MMTV-PyMT;Ccr2+/+ mice and was not significantly different
from that of MMTV-PyMT;Ccr2−/− mice (Fig. S1 H). There were
also no significant differences in the number of metastatic foci
(representing seeding density) related to the Ccr2 genotype (Fig.
S1 I). However, we found that the metastatic foci were larger in
the lungs of MMTV-PyMT;Ccr2+/+ mice than in the lungs of
MMTV-PyMT;Ccr2−/− mice (Fig. S1 J), suggesting that CCR2
promotes the growth of secondary lesions.
Ccr2 expression in cancer cells is associated with poor
differentiation and reduced apoptosis sensitivity
The tumors from transplanted Ccr2+/+ or Ccr2−/− cancer cells were
markedly different at the histological level (Fig. 2 A), similar to the
autochthonous tumors in theMMTV-PyMT;Ccr2−/− animals (Fig. S1,
B and C). The tumors originating from Ccr2+/+ cancer cells consisted
entirely of microlobules composed of sheets of large, neoplastic
epithelial cells. Themicrolobuleswere surrounded by small amounts
of fibrovascular stroma containing dense collagen, which is charac-
teristic of poorly differentiated MMTV-PyMT tumors. The neo-
plastic cells had round-to-oval nuclei, prominent nucleoli, scant
cytoplasm, and indistinct cell borders, typical of undifferentiated
cells. In contrast, the tumors originating from Ccr2−/− cancer cells
were more differentiated. In many areas, the cancer cells con-
tained lipid vacuoles of various sizes. These tumors also had large
cystic areas lined by a single or double layer of small, polarized
epithelial cells, and the lumina were filled with proteinaceous
secretions (Fig. 2 A). Conversely, the tumors originating from
Ccr2−/− cancer cells had a reduced percentage of solid areas com-
pared with those originating from Ccr2+/+ cancer cells (Fig. 2 B).
To understand why tumors from Ccr2−/− cancer cells grew
more slowly than tumors from Ccr2+/+ cancer cells, we next
examined the rates of proliferation and apoptosis in the tumors
collected during the phase when Ccr2−/− tumors were growth
restricted, 5–6 wk after transplantation. There was no difference
in proliferation as determined by nuclear Ki67 staining (Fig. 2
C), and primary Ccr2+/+ and Ccr2−/− cancer cells also grew sim-
ilarly in vitro (Fig. 2 D). However, we found a higher percentage
of cancer cells undergoing apoptosis in tumors from Ccr2−/−
cancer cells than from Ccr2+/+ cancer cells (Fig. 2 E). Further-
more, Ccr2−/− cancer cells were more sensitive to serum-free
conditions (Fig. 2 F), consistent with a previous study showing
that CCR2 signaling can protect cancer cells from apoptosis in-
duced by serum starvation (Fang et al., 2012).
Ccr2−/− cancer cells have increased expression of interferon
(IFN) response genes and of genes involved in MHC class I
antigen presentation
To determine which pathways in the Ccr2−/− cancer cells led to
reduced tumor growth and increased cell death, we isolated
cancer cells from Ccr2+/+ and Ccr2−/− transplanted tumors formed
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Figure 1. Cancer cell Ccr2 promotes primary tumor growth, reducing overall survival. (A) Tumor onset (tumor-free survival) is similar for MMTV-PyMT;
Ccr2+/+, MMTV-PyMT;Ccr2+/−, and MMTV-PyMT;Ccr2−/− mice, as determined by weekly palpation and caliper measurement (log-rank [Mantel-Cox] test; n =
28 MMTV-PyMT;Ccr2+/+, 20 MMTV-PyMT;Ccr2+/−, and 18 MMTV-PyMT;Ccr2−/− mice). (B) Primary tumor growth is reduced in MMTV-PyMT;Ccr2+/− and
MMTV-PyMT;Ccr2−/− mice compared with MMTV-PyMT;Ccr2+/+ mice, as determined by weekly caliper measurements (Welch’s ANOVA followed by Dunnett’s
T3 multiple comparisons test was performed to compare tumor volume at the 8-wk time point [last time point before many MMTV-PyMT;Ccr2+/+ mice were
euthanized due to large tumor burden]; n = 21 MMTV-PyMT;Ccr2+/+, 25 MMTV-PyMT;Ccr2+/−, and 18 MMTV-PyMT;Ccr2−/− mice). (C) Time until IACUC-
approved endpoint was increased for MMTV-PyMT;Ccr2+/− and MMTV-PyMT;Ccr2−/− mice compared with MMTV-PyMT;Ccr2+/+ mice (log-rank [Mantel-Cox]
test, Bonferroni corrected; n = 30 MMTV-PyMT;Ccr2+/+, 35 MMTV-PyMT;Ccr2+/−, and 29 MMTV-PyMT;Ccr2−/−mice). (D) Cancer cells express CCR2 (arrows) as
determined by RNA ISH for Ccr2 performed on paraffin-embedded tumor sections from MMTV-PyMT;Ccr2+/+ mice. Image is representative of >10 mice. Scale
bar = 20 µm. (E) CCR2 is expressed on epithelial cells, as determined by flow cytometry performed on Ccr2+/+ or Ccr2−/− tumors transplanted to C57BL/6 hosts.
Anti-CCR2 primary antibody was gated on EpCAM+ cells and compared with background levels. Left panel shows one representative experiment, and right
panel depicts median fluorescence intensity for all experiments (Student’s t test; n = 5). (F) Schematic of transplantation experiments. (G) Primary tumor
growth of Ccr2−/− cancer cells is reduced compared with that of Ccr2+/+ cancer cells regardless of the Ccr2 genotype of the host, as determined by weekly
caliper measurements (one-way ANOVAwas performed for the tumor volume analysis at day 33 [last time point with all Ccr2+/+ hosts transplanted with Ccr2+/+
cancer cells alive] and at day 40 [last time point with all Ccr2−/− hosts transplanted with Ccr2+/+ cancer cells alive], followed by Sidak’s multiple comparisons
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in wild-type hosts for equal amounts of time and performed
transcriptome profiling by RNA sequencing (RNA-seq).
Overall, 520 genes were differentially expressed (adjusted P
value <0.05), ∼40% of which were up-regulated in Ccr2−/−
cancer cells compared with Ccr2+/+ cancer cells. Among the
differentially expressed genes, we detected up-regulation of
MHC class I (H2-K1) and Tap1, two genes required for antigen
presentation, and IFI27, an IFN response gene, in the Ccr2−/−
cancer cells (Fig. 3 A). Vimentin, which is found in poorly
differentiated epithelial cells and in mesenchymal cells, was
down-regulated in Ccr2−/− cancer cells. This is consistent with
a previous study describing a mesenchymal and invasive
phenotype in CCR2-expressing cancer cells (Hu et al., 2019).
Additionally, gene set enrichment analysis showed robust
expression enrichment of the IFN-γ response hallmark gene
set, which included genes involved in antigen processing and
presentation, in Ccr2−/− cancer cells compared with Ccr2+/+
cancer cells (Fig. 3 B). We also observed a pronounced luminal
gene expression signature in the Ccr2−/− cancer cells (Fig. 3 B),
in agreement with the noted histological differences (Fig. 2, A
and B). Consistently, gene ontology (GO) term analysis re-
vealed altered expression of pathways involved in (1) regulation
test; Student’s t test was performed for the tumor volume analysis at day 68 [last time point with all Ccr2−/− hosts transplanted with Ccr2−/− cancer cells alive];
n = 8 for all conditions). (H) Survival until IACUC-defined endpoint is increased in mice bearing Ccr2−/− cancer cells regardless of the genotype of the host (log-
rank [Mantel-Cox] test; n = 4 for all conditions). Means ± SEM are indicated (B, E, and G). P values were determined by the tests indicated. *, P < 0.05; **, P <
0.01; ***, P < 0.001. N.S., nonsignificant.
Figure 2. Loss of Ccr2 increases apoptosis in vivo with no effect on proliferation. (A) Four representative photomicrographs of H&E-stained tumors
derived from Ccr2+/+ and Ccr2−/− cancer cells. Arrows denote cystic areas. Also note lipid vacuoles in tumors from Ccr2−/− cancer cells. Scale bar = 100 µm.
(B) Histology score of solid area in tumors from Ccr2+/+ and Ccr2−/− transplants (n = 10 in Ccr2+/+, and n = 8 in Ccr2−/−). (C) Proliferation is unchanged between
Ccr2+/+ and Ccr2−/− tumor transplants during the growth-restricted phase, as determined by Ki67-positive nuclear stain. Left panels are representative
photomicrographs (scale bar = 100 µm), and right panel shows quantification (n = 10 and 9 for Ccr2+/+ and Ccr2−/− transplants, respectively). (D) Proliferation is
unchanged in Ccr2+/+ and Ccr2−/− cancer cells in vitro during the growth-restricted phase, as determined by absorbance after 24 h using CellTiter 96 AQueous
One Solution Cell Proliferation (MTS) Assay (n = 4). (E) Ccr2−/− cancer cells have an increased apoptotic index compared with Ccr2−/− cancer cells during the
growth-restricted phase, as determined by double immune staining for PyMT and cleaved caspase-3. Left panels are representative photomicrographs, with
arrows indicating apoptotic cancer cells (scale bar = 100 µm); right panel shows quantification (n = 5). Each dot represents an average of five random fields of
views from one tumor. (F) Ccr2−/− cancer cells are less viable than Ccr2+/+ cancer cells in serum-free conditions, as determined by absorbance in MTS assay
after serum starvation for 24 h (n = 3). Means ± SEM are indicated. P values were determined by Student’s t test. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
N.S., nonsignificant.
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of the adaptive immune system and in (2) response to immune-
mediated cell killing (Fig. 3 C).
Cancer cell CCR2 promotes immune suppression
The increased expression of genes associated with IFN response
and antigen presentation, together with the prolonged growth
delay and increased apoptosis in tumors from Ccr2−/− cancer
cells, is consistent with an ongoing adaptive immune response in
the tumors. We therefore determined whether there were any
differences in the infiltrating immune cell populations by flow
cytometry (for gating strategy, see Fig. S2). There were signifi-
cantly more CD8+ CTLs and fewer CD4+ helper T cells in tumors
from Ccr2−/− cancer cells than in tumors from Ccr2+/+ cancer cells
(Fig. 4 A), with no overall change in CD3+ T cell infiltration (Fig.
S3 A). Increased infiltration of CD8+ cells into tumors derived
from Ccr2−/− cancer cells was also evident by immunofluores-
cence (Fig. 4, B and C). PD-1 is an inhibitory checkpoint surface
molecule expressed by activated CD8+ T cells (Chen et al., 2016a),
and its expression was increased on CD8+ T cells from tumors
from Ccr2−/− cancer cells (Fig. 4 D). CTLs kill, in part, through the
release of granzyme B, a process that requires lysosomal-
associated membrane protein 1 (LAMP-1; also known as Clus-
ter of Differentiation 107a [CD107a]). In tumors from Ccr2−/−
cancer cells, LAMP-1 was increased on the cell surface of CD8+
T cells (Fig. 4 E), while granzyme B levels were reduced in CD8+
T cells (Fig. 4 F), indicating increased levels of prior CD8+ de-
granulation and therefore cytotoxic activity. Regulatory T lym-
phocytes (CD4+FoxP3+ regulatory T cells), which are typically
immunosuppressive, were more abundant in tumors from Ccr2−/−
cancer cells (Fig. S3 B).
Tumors from Ccr2−/− cancer cells had multiple changes in
the adaptive immune cell infiltrate, all consistent with an
active immune response. Therefore, we tested whether an
adaptive immune response contributed to the differences in
growth rates between the Ccr2+/+ and Ccr2−/− tumors by
transplanting cancer cells in parallel into T cell–deficient
athymic (nude) or fully immunocompetent mice (Fig. 5 A). In
the immunocompetent hosts, tumors from Ccr2−/− cancer cells
Figure 3. Ccr2−/− cancer cells have increased expression of IFN response genes and of genes involved in MHC class I antigen presentation. (A) A
hierarchically clustered heat map of Ccr2+/+ and Ccr2−/− cancer cell samples collected during the growth-restricted phase, based on expression levels of select
genes associated with antigen processing and presentation, as well as epithelial-to-mesenchymal transition (n = 3 for Ccr2+/+ and Ccr2−/− tumors). (B) Gene set
enrichment analysis plots showing enrichment of IFN-γ response and luminal gene set expression in Ccr2−/− cancer cells. NES, normalized enrichment score.
(C) GO term enrichment plots showing the most significantly overrepresented GO terms in Ccr2−/− cancer cells compared with Ccr2+/+ cancer cells. Statistical
analyses for RNA-seq data are described in the Materials and methods section. FDR, false discovery rate; max, maximum; min, minimum; proc., processing;
pres., presentation.
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grew significantly more slowly than tumors from Ccr2+/+
cancer cells (Fig. 5 B), as previously observed (Fig. 1 G). In
contrast, in the T cell–deficient hosts, the Ccr2−/− tumors grew
at a similar rate as the Ccr2+/+ tumors (Fig. 5 C). Consistently,
tumors derived from Ccr2−/− cancer cells grew as fast as tu-
mors derived from Ccr2+/+ cancer cells when CD8+ T cells were
depleted from wild-type mice (Fig. S3 C). Furthermore, in the
T cell–deficient, athymic hosts, tumors from Ccr2−/− cancer
cells no longer had more apoptotic cells than tumors from
Ccr2+/+ cancer cells (Fig. 5 D). Interestingly, the differentiated
histological phenotype of the tumors from the Ccr2−/− cancer
cells was maintained in the athymic mice (Fig. 5, E and F).
Thus, the histological differences were not the result of an
altered adaptive immune response. Together, these data dem-
onstrate that CCR2 expressed by cancer cells enables the tumors
to escape the adaptive immune response.
We next speculated that the reduced growth of tumors from
Ccr2−/− cancer cells could be a result of increased sensitivity to
CTL-induced cell death, given that the Ccr2−/− cancer cells
showed increased sensitivity to serum-free conditions and that
the tumors grew normally when CD8+ T cells were depleted.
To test this possibility, we used the MMTV-PyMT–mCherry-
OVA (chOVA) model (Engelhardt et al., 2012), which is driven
by the PyMT oncogene and coexpresses OVA as a model tumor
antigen and mCherry for tracking. We generated MMTV-
PyMT-chOVA;Ccr2+/+ and MMTV-PyMT-chOVA;Ccr2−/− mice
and found that similar to the MMTV-PyMT;Ccr2−/− tumors,
the MMTV-PyMT-chOVA;Ccr2−/− tumors grew more slowly
than MMTV-PyMT-chOVA;Ccr2+/+ tumors (Fig. 6 A). When
primary cancer cells were isolated and challenged with acti-
vated CTLs isolated from OT-1 mice (where T cells are en-
gineered to recognize an OVA peptide presented by MHC class
Figure 4. Tumors derived from Ccr2−/− cancer cells have increased infiltration of activated CTLs. (A) Tumors from Ccr2−/− cancer cells have fewer CD4+
T cells and more CD8+ T cells during the growth-restricted phase, as determined by flow cytometry gated on CD45+CD3+ cells. Left panels are representative
examples of dot plots, and right panels show quantification of CD4+ and CD8+ cells (n = 5). (B) Representative immunofluorescence staining showing that more
CD8a+ T cells (red) infiltrate into tumors derived from Ccr2−/− cancer cells than tumors from Ccr2+/+ cancer cells during the growth-restricted phase (scale bar =
100 µm). (C)Quantification of CD8a+ T cells in the tumors (n = 5 tumors; each dot represents the average of five random fields of views of one tumor). (D) PD-1 levels
were increased in CD8+ T cells in tumors from Ccr2−/− cancer cells during the growth-restricted phase, as determined by flow cytometry gating on CD45+CD3+CD8+
cells (n = 5). (E) LAMP-1 (CD107a) levelswere increased in CD8+ T cells in Ccr2−/− tumors during the growth-restricted phase, as determined by flow cytometry gated on
CD45+CD3+CD8+ cells (n = 4 and 5 for Ccr2+/+ and Ccr2−/− transplants, respectively). (F) Intracellular granzyme B levels were decreased in CD8+ T cells in Ccr2−/− tumors
during the growth-restricted phase, as determined by flow cytometry gated on CD45+CD3+CD8+ cells, after 2 h of incubation with Brefeldin A (n = 5). Means ± SEM are
indicated. P values were determined by Student’s t test. *, P < 0.05 (A and D–F); ****, P < 0.0001 (C).
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I), we found that MMTV-PyMT-chOVA;Ccr2−/− cancer cells
were approximately twice as sensitive to CTLs as MMTV-
PyMT-chOVA;Ccr2+/+ cancer cells (Fig. 6 B). Upon treatment
with a pharmacological inhibitor against CCR2 (RS 102895
hydrochloride; Mitchell et al., 2013), the MMTV-PyMT-chOVA;
Ccr2+/+ cancer cells became as sensitive to the OVA-specific
CTLs as the MMTV-PyMT-chOVA;Ccr2−/− cancer cells (Fig. 6
C). The CCR2 inhibitor also increased specific cytolysis of the
OVA-expressing E0771 murine breast cancer cell line to the
OVA-specific CTLs (Fig. S3 D). In contrast, the CCR2 inhibitor
had no effect on the specific cytotoxicity of the CTLs to the
MMTV-PyMT-chOVA;Ccr2−/− cancer cells (Fig. 6 C).
To test if Ccr2 expression in cancer cells also regulated sen-
sitivity to CTLs in vivo, we measured the clonal expansion of
T cells, an indicator of active proliferation of antigen-specific
T cells, by sequencing the complementarity determining
Figure 5. Cancer cell Ccr2 tumor growth requires functional adaptive immunity. (A) Schematic of experimental design. (B) Tumors from Ccr2+/+ cancer
cells grow faster than tumors from Ccr2−/− cancer cells in mice with intact immune systems. Tumor burden was determined by weekly caliper measurements.
Mice were sacrificed at IACUC-approved endpoint (n = 20 per condition). (C) Tumors from Ccr2+/+ cancer cells grow similarly to tumors from Ccr2−/− cancer
cells in athymic host mice. Tumor burden was determined by weekly caliper measurement. Mice were sacrificed at IACUC-approved endpoint (n = 20 per
condition). (D) Apoptosis was unchanged between Ccr2+/+ and Ccr2−/− transplants to athymic hosts, as determined by TUNEL stain. Left panels are repre-
sentative photomicrographs (scale bar = 100 µm), with arrows pointing to apoptotic cells; right panel shows quantification (n = 8 and 6 for Ccr2+/+ and Ccr2−/−
transplants, respectively). (E) Representative H&E staining of transplanted tumors from Ccr2+/+ and Ccr2−/− cancer cells to nude hosts. Arrows indicate highly
necrotic areas (scale bar = 100 µm). (F) Histology score of solid area of transplanted tumors from Ccr2+/+ and Ccr2−/− cancer cells to athymic hosts (n = 10 in
Ccr2+/+ and n = 9 in Ccr2−/−). Means ± SEM are indicated. P values were determined by t test with Welch’s correction (B) or by Student’s t test (C) for tumor
volume analysis at the end time point and by Student’s t test (D and F). *, P < 0.05; **, P < 0.01. N.S., nonsignificant.
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region 3 (CDR3) region of the T cell receptor (TCR) β chain. We
found that clonality, a value corresponding to the extent of
clonal expansion of T cells (Fig. 6 D), was significantly higher in
tumors from Ccr2−/− cancer cells than in tumors from Ccr2+/+
cancer cells (Fig. 6 E), while there was no difference in clonality
in the spleens of these groups of mice (Fig. 6 F). These results
suggested that tumor-recognizing CTLs were actively expanding
due to antigen recognition in tumors from Ccr2−/− cancer cells,
but that this expansion did not alter the systemic T cell response.
Both Ccr2+/+ and Ccr2−/− cancer cells express the PyMT tumor
antigen, and Ccr2+/+ cancer cells formed tumors at the same rate
regardless of whether Ccr2+/+ or Ccr2−/− cancer cells were trans-
planted to the contralateral mammary gland (Fig. S3 E). Together,
these results suggest that the expression of CCR2 by cancer cells
enables the tumors to establish a locally immune-suppressive
microenvironment.
Cancer cell CCR2 alters MHC class I and PD-L1 expression
CCR2 signaling can activate STAT transcription factors in
cancer cells (Chen et al., 2015; Izumi et al., 2013), and altered
Figure 6. Cancer cell Ccr2 signaling protects against T cell–mediated killing. (A) Primary tumor growth is reduced in MMTV-PyMT-chOVA;Ccr2−/− mice
compared with MMTV-PyMT-chOVA;Ccr2+/+ mice, as determined by weekly caliper measurements once the tumors were palpable (n = 6 MMTV-PyMT;Ccr2+/+
mice, and n = 5MMTV-PyMT;Ccr2−/−mice). (B) Ccr2−/− cancer cells aremore sensitive to T cell cytotoxicity than Ccr2+/+ cancer cells. Cytotoxicity of CD8+ OT-1 T cells
toward MMTV-PyMT-chOVA;Ccr2+/+ or MMTV-PyMT-chOVA;Ccr2−/− primary cancer cells, with or without OVA peptides, measured by chromium (Cr51) release
(n = 3). (C) Inhibiting CCR2 increased T cell cytotoxicity against Ccr2+/+ cancer cells. Cytotoxicity of CD8+ OT-1 T cells toward MMTV-PyMT-chOVA;Ccr2+/+ or
MMTV-PyMT-chOVA;Ccr2−/− cancer cells, with or without CCR2 inhibitor, measured by chromium (Cr51) release (each dot is the average of triplicate from an
independent experiment; n = 4 and 3 for MMTV-PyMT-chOVA;Ccr2+/+ and MMTV-PyMT-chOVA;Ccr2−/− cancer cells, respectively). (D) Model of clonality
measured by TCR sequencing. (E) Productive clonality in tumors from Ccr2+/+ and Ccr2−/− cancer cells (n = 4). (F) Productive clonality in spleens was unchanged
between Ccr2+/+ and Ccr2−/− tumors (n = 4). Statistical analysis of TCR sequencing data is described in the Materials and methods section. Means ± SEM are
indicated. P values were determined for tumor volume analysis at the end time point using t test withWelch’s correction (A) or Student’s t test (B, C, E, and F). *,
P < 0.05. N.S., nonsignificant.
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STAT1 or STAT3 signaling in cancer cells can in turn lead to a
less immune-suppressive microenvironment (Ahn et al.,
2017; Jones et al., 2016). Therefore, we tested whether
STAT activation was different between tumors from Ccr2+/+
and Ccr2−/− cancer cells. We found no consistent differences
between the activation of STAT1, STAT3, or p65/RELA when
whole tumor lysate was assayed by Western blot (Fig. 7 A).
By immunohistochemistry, we found that the tumors con-
tained patches of cancer cells with high expression of phospho-
STAT1, with more of these patches in the tumors from
Ccr2−/− than from Ccr2+/+ cancer cells (Fig. 7, B and C). No
difference was observed for phospho-STAT3. This suggested
a localized, enhanced anti-tumor immune response regulated
via STAT1 in tumors from Ccr2−/− cancer cells compared with
those from Ccr2+/+ cells, consistent with other reports (Avalle
et al., 2012).
We next sought to understand how CCR2 signaling in
cancer cells resulted in more efficient immune suppression.
RNA-seq analysis of the cancer cells showed increased ex-
pression of genes involved in antigen presentation in the
Ccr2−/− tumors (Fig. 3 A). Consistently, we found high levels
of MHC class I expressed by cancer cells in MMTV-PyMT-
chOVA;Ccr2−/− mice compared with the variable, low to
intermediate levels expressed by cancer cells in MMTV-
PyMT-chOVA;Ccr2+/+ mice (Fig. 8 A). Similarly, when cancer
cells were transplanted to immunocompetent host mice,
expression of MHC class I was higher by Ccr2−/− cancer cells
than by Ccr2+/+ cancer cells, as shown by immunofluores-
cence (Fig. 8 B). However, in T cell–deficient, athymic host
mice, MHC class I levels were similar on Ccr2+/+ and Ccr2−/−
cancer cells (Fig. 8 C). These data suggest that MHC class I
expression is not directly regulated by CCR2 signaling in the
Figure 7. Localized STAT1 activation in Ccr2−/− tumors. (A) Left: Comparison of STAT1 activation in tumors from Ccr2+/+ or Ccr2−/− cancer cells during the
growth-restricted phase by Western blot analysis. Each lane contains a protein sample from a tumor from a different mouse. Proteins with similar molecular
weight were detected using blots from separate gels, loaded with equal amounts of samples. Right: Quantifications of protein expression normalized to β-actin
levels (n = 4 for Ccr2+/+, and n = 5 for Ccr2−/−). (B) Representative photomicrographs of p-STAT1 (top) and p-STAT3 (bottom) staining in sections of tumors from
Ccr2+/+ or Ccr2−/− cancer cells. Scale bar = 100 µm. (C) Quantification of the immunohistochemical staining in B using H-score shows higher STAT1 phos-
phorylation in tumors from Ccr2−/− than in those from Ccr2+/+ cancer cells but similar levels of STAT3 phosphorylation (n = 5). Means ± SEM are indicated.
P values were determined by Student’s t test. *, P < 0.05. N.S., nonsignificant.
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Figure 8. MHC class I expression is reduced and PD-L1 expression increased in Ccr2+/+ cancer cells in immunocompetent mice. (A) MHC class I
expression is increased in MMTV-PyMT-chOVA;Ccr2−/− tumors compared with MMTV-PyMT-chOVA;Ccr2+/+ tumors during the growth-restricted phase, as
determined by immunofluorescence staining (upper panels: representative images; scale bar = 50 µm) and by flow cytometry (bottom panel), gated on
EpCAM+, mCherry+ cells (n = 8 and 4 for PyMT-chOVA;Ccr2+/+ and PyMT-chOVA;Ccr2−/− tumors, respectively). (B)MHC class I is increased on Ccr2−/− compared
with Ccr2+/+ cancer cells after transplantation into C57BL/6 hosts during the growth-restricted phase, as determined by immunofluorescence staining (upper
panels; scale bar = 50 µm). Quantification of mean pixel count (bottom panel, n = 5). (C)MHC class I is unchanged on Ccr2+/+ and Ccr2−/− cancer cell transplants
to athymic hosts, as determined by immunofluorescence staining (upper panels; scale bar = 50 µm). Quantification of mean pixel count (bottom panel, n = 4
and 5 for Ccr2+/+ and Ccr2−/− transplants, respectively). (D) PD-L1 is decreased on Ccr2−/− cancer cells, as determined by flow cytometry gated on EpCAM+ cells
(n = 5). (E) PD-L1 mRNA levels are decreased in cultured Ccr2−/− cancer cells, but the cells respond equally well to IFN-γ treatment as Ccr2−/− cancer cells, as
determined by qPCR. Ccr2+/+ and Ccr2−/− cancer cells growing in culture were treated with either 0, 0.2, 2.0, or 20 ng/ml of recombinant IFN-γ for 48 h (n = 3).
(F) Treatment with four intraperitoneal doses of anti–PD-L1 antibody (200 µg/injection) had no significant effect on growth of Ccr2+/+ or Ccr2−/− tumors in vivo
compared with control rat IgG antibody (arrows indicate treatments; n = 20 tumors for all conditions). Means ± SEM are indicated. P values were determined by
Student’s t test (A–E) or Student’s t test on day 58 for Ccr2+/+ transplants (black lines in F) and at day 75 for Ccr2−/− transplants (red lines in F). *, P < 0.05; **,
P < 0.01; ***, P < 0.001. N.S., nonsignificant.
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cancer cells, but rather is regulated by the different immune
responses between these tumors.
PD-L1 is a potent suppressor of T cell activation and prolif-
eration and is expressed on many types of cancer cells (Freeman
et al., 2000). Expression of PD-L1 was significantly higher on
Ccr2+/+ cancer cells than on Ccr2−/− cancer cells (Fig. 8 D). Since
both MHC class I and PD-L1 are IFN-γ response genes, we
compared Ifn-gmRNA levels during the early tumor phase (3 wk
after transplantation) and found significantly higher levels of
Ifn-g, as well as Cxcl9, in whole tumor lysate from tumors
derived from Ccr2−/− compared with Ccr2+/+ cancer cells by
real-time quantitative PCR (RT-qPCR; Fig. S4 A). RNA FISH re-
vealed that the majority of the Ifn-g mRNA was expressed by
infiltrating CD8+ T cells and that Ifn-g levels were more variable
during the growth-restricted phase of tumors than during the
early tumor establishment phase (Fig. S4, B–D). In vitro, re-
combinant IFN-γ treatment resulted in similar up-regulation of
Pd-l1 mRNA levels in Ccr2+/+ and Ccr2−/− cancer cells (Fig. 8 E).
Thus, our data suggest that Ccr2−/− cancer cells would be able to
respond to increased IFN-γ levels in the tumor microenviron-
ment by up-regulating PD-L1. Since we see reduced PD-L1 ex-
pression on the Ccr2−/− cancer cells in vivo in the context of
elevated Ifn-g, other factors must repress PD-L1 expression
in vivo. Lastly, we tested whether PD-L1 blockade would alle-
viate immune suppression of the MMTV-PyMT tumors in vivo.
However, anti–PD-L1 therapy had no significant effect on the
growth of either the Ccr2+/+ tumors or the low PD-L1–expressing
Ccr2−/− tumors (Fig. 8 F). Thus, although reduced PD-L1 likely
contributed to an increased sensitivity to CTLs in tumors from
Ccr2−/− cancer cells, targeting PD-L1 expression was insufficient
to reduce growth of the Ccr2+/+ tumors.
Cancer cell CCR2 prevents the infiltration of cross-presenting
CD103+ DCs
We next examined the infiltration levels of immune populations
that might be involved in immune suppression in the Ccr2+/+
tumors. There was no difference in CD11b+MHC class II+F4/80+
macrophages between tumors from Ccr2+/+ and Ccr2−/− cancer
cells (Fig. S4 E). There were, however, significantly fewer
CD11b+MHC class II−myeloid cells in tumors from Ccr2−/− cancer
cells (Fig. S4 F). This population includes subsets of MDSCs,
immature myeloid cells with immune-suppressive activity.
Specifically, we found fewer granulocytes and granulocytic
MDSCs (CD11b+CD11c−Ly6G+Ly6Clow cells) andmore inflammatory
monocytes and myeloid MDSCs (CD11b+CD11c−Ly6G−Ly6Chigh
cells) in tumors from Ccr2−/− cancer cells than in those from
Ccr2+/+ cancer cells (Fig. S4, G and H).
Since DCs are critical for T cell activation, we performed
immunofluorescence for CD11c+, a marker of DCs, and observed
more infiltrating CD11c+ cells in the tumors derived from Ccr2−/−
cancer cells than in those derived from Ccr2+/+ cancer cells (Fig. 9
A). Furthermore, we foundmore than double the level of CD103+
DCs—a DC subtype that is very proficient in cross-presenting
antigens to CD8+ T cells—in tumors from Ccr2−/− cancer cells
than in those from Ccr2+/+ cancer cells (Fig. 9 B). The number of
CD103+ DCs was also increased in the draining lymph nodes
(dLNs) for these tumors (Fig. 9 C). A concern when using a
transplant system to evaluate immune response is the potential
for an immune reaction toward antigens on the transplanted
cells. However, there were also more CD103+ DCs in the spon-
taneously developing tumors in MMTV-PyMT;Ccr2−/− mice than
in MMTV-PyMT;Ccr2+/+ mice (Fig. S4 I). Using RT-qPCR from
whole tumor lysate and a panel of markers previously shown to
be enriched in CD103+ DCs (Broz et al., 2014), we detected more
mRNA for Cd11c and from activation markers, including Cd80,
Cd86, and Il12b (Fig. 9 D). Consistently, DCs in tumors from
Ccr2−/− cancer cells displayed higher levels of CD86, a surface
marker up-regulated on activated DCs as determined by flow
cytometry (Fig. 9 E). The difference in CD103+ DC numbers was
already apparent in the dLNs 2 d after injection of irradiated
cancer cells into the mammary fat pad (Fig. 9 F), suggesting a
direct signal from the cancer cells. However, infiltration of
CD103+ DCs was not increased in tumors from Ccr2−/− cancer
cells in T cell–deficient, athymic mice (Fig. 9 G). This finding
suggests that a feedback loop between T cells and DCs is critical
for CD103+ DC recruitment to the tumors.
We next asked whether a factor secreted by Ccr2−/− cancer
cells was responsible for DC maturation toward the CD103+ DC
subtype. Indeed, when bone marrow–derived cells (BMDCs)
were cultured with conditioned medium from Ccr2−/− or Ccr2+/+
cancer cells, the total number of DCs was not different, but a
significantly higher percentage of CD11c+ cells was positive for
CD103+ using conditioned medium from the Ccr2−/− cells (Fig. 10
A). Furthermore, the percentage of CD103+CD11c+ cells also in-
creased when using conditioned medium from Ccr2+/+ cancer
cells that had been treated with the CCR2 inhibitor (Fig. 10 B),
whereas adding the CCR2 inhibitor directly to the bone
marrow–derived cultures did not by itself increase the per-
centage of CD103+ cells. Both Flt3 ligand and GM-CSF can
stimulate DC maturation toward the CD103+ subtype (Broz et al.,
2014). Consistently, we found more mRNA for both Flt3l and Csf2
(coding for GM-CSF) in the tumors derived from Ccr2−/− cancer
cells than from Ccr2+/+ cancer cells by RT-qPCR (Fig. 10 C).
Protein arrays showed that the levels of two CCR2 ligands, CCL2
and CCL12, and most other cytokines were similar between
MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2−/− tumors (Fig. S5
A), while IL-16 and granulocyte colony-stimulating factor
(G-CSF) were significantly lower in the MMTV-PyMT;Ccr2−/−
tumors at the protein level. When secretions from overnight
cultures of the cancer cells under serum-free conditions were
analyzed, no significant differences were detected (Fig. S5 B).
Thus, from these different assays measuring protein and mRNA,
Flt3L, G-CSF, and GM-CSF emerged as candidate factors for fu-
ture functional studies to determine how CD103+ DC maturation
is altered downstream of CCR2 signaling in cancer cells.
Lastly, to test the importance of the CD103+ DCs in regulating
an immune-controlling microenvironment, we transplanted
Ccr2−/− and Ccr2+/+ cancer cells into Batf3−/− mice, which lack the
basic leucine zipper transcription factor ATF-like 3 (BATF3)
critical for CD103+ DC maturation. In these mice, the growth of
Ccr2−/− cancer cell–derived tumors was restored to that of the
Ccr2+/+ cancer cell–derived tumors (Fig. 10 D), and as expected,
the percentage of infiltrating CD103+ DCs was significantly re-
duced (Fig. 10 E). Furthermore, CD8+ T cell infiltration, as well as
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expression of CD107a and PD-1 by the T cells, was reduced in
tumors derived from Ccr2−/− cancer cells transplanted into
Batf3−/− mice (Fig. 10, F–H). These findings support the notion
that CD103+ DC and CD8+ T cells act together to regulate tumor
immunity.
Discussion
The tumor-promoting effects of CCR2 are well documented.
However, they have mostly been attributed to CCR2-expressing
immune and other host cells (Lim et al., 2016; Nakasone et al.,
2012; Qian et al., 2009, 2011; Wolf et al., 2012). Yet, CCR2 is also
expressed by breast cancer cells and possibly up-regulated
compared with normal breast epithelial tissue in a subset of
breast cancers, and such expression has been correlated with
shortened survival (Labovsky et al., 2017). The expression of
CCR2 by cancer cells has been proposed to promote tumor
growth through increased motility and invasion, cell prolifera-
tion, and cell survival (Fang et al., 2012; Hu et al., 2019; Lu et al.,
2006). Here, we showed that in the MMTV-PyMTmouse model,
CCR2 signaling in cancer cells helps breast tumors establish a
locally immune-suppressive microenvironment. Compared with
tumors from Ccr2+/+ cancer cells, the tumors from Ccr2−/− cancer
cells have higher infiltration of CD103+ DCs and activated CD8+
T cells, as well as lower infiltration of granulocytic MDSCs.
Furthermore, the Ccr2−/− cancer cells have higher surface levels
of MHC class I and lower levels of PD-L1. It is likely the com-
bination of all of these changes that results in more effective
Figure 9. Ccr2−/− tumors promote infiltration and activation of cross-presenting CD103+ DCs. (A) Representative immunofluorescence images showing
that more CD11c+ DCs (red) infiltrated into Ccr2−/− tumors compared with Ccr2+/+ tumors during the growth-restricted phase (EpCAM+, green; scale bar = 100
µm). (B) CD103+ DCs are increased in Ccr2−/− tumors compared with Ccr2+/+ tumors during the growth-restricted phase, as determined by flow cytometry
gated on CD45+CD11c+MHC class II+ cells. SSC, side scatter (n = 5). (C) CD103+ DCs are increased in the dLNs of Ccr2−/− tumors compared with the dLNs of
Ccr2+/+ tumors during the growth-restricted phase, as determined by flow cytometry gated on CD45+CD11c+MHC class II+ cells (n = 5). (D) Tumors from
transplanted Ccr2−/− cancer cells have increased DC infiltration and elevated markers of DC activation compared with tumors from Ccr2+/+ cancer cells. RT-
qPCR on tumors during the growth-restricted phase (for Cd11c, n = 6 in Ccr2+/+ and n = 8 in Ccr2−/−; for other genes, n = 5 in Ccr2+/+ and n = 6 in Ccr2−/−). (E) DCs
in Ccr2−/− tumors are more activated during the growth-restricted phase, as determined by flow cytometry for CD86+ gated on CD45+CD11c+MHC class II+ cells
(n = 5). (F) Flow cytometry on dLNs with or without injection of irradiated cancer cells into the mammary gland. Note that CD103+ DCs are only increased in the
dLNs of the glands after injection of Ccr2−/− cancer cells, not in non-dLNs from axillary glands (n = 5). (G) CD103+ DCs are decreased in Ccr2−/− tumors
compared with Ccr2+/+ tumors in athymic hosts, as determined by flow cytometry gated on CD45+CD11c+ cells (n = 5). Means ± SEM are indicated. P values
were determined by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. N.S., nonsignificant.
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immune surveillance of the Ccr2−/− cancer cells and reduced
growth of tumors from these cells. To our knowledge, the ability
of cancer cell CCR2 signaling to orchestrate tumor immune
suppression has not previously been recognized.
Among the most notable changes in the tumor immune mi-
croenvironment caused by targeting cancer cell Ccr2 were the
increased levels of both CD103+ DCs and CD8+ T cells in tumors,
and the infiltration of these two cell populations was apparently
connected. In athymic mice lacking mature CD8+ cells, the
CD103+ DC infiltration was no longer elevated in tumors derived
from Ccr2−/− cancer cells compared with those from Ccr2+/+
cancer cells. Conversely, in Batf3−/− mice, which lack the tran-
scription factor BATF3 required for CD103+ DC development,
CD8+ T cell infiltration was equally low for tumors from Ccr2+/+
and Ccr2−/− cancer cells. These observations are consistent with
several other recent reports intimately linking the function of
CD103+ DCs and CD8+ T cells in tumors. First, CD103+ DCs have
been shown to secrete chemokines mediating T cell infiltration,
including CXCL9 and -10 (de Mingo Pulido et al., 2018; Spranger
et al., 2017). Second, secretion of IL-12 from CD103+ DCs has been
shown to stimulate CD8+ T cell function (Ruffell et al., 2014). Our
data support these previous studies, showing not only a link
between CD103+ DC and CD8+ T cell infiltration but also in-
creased Cxcl9 and Il-12b mRNA in tumors derived from Ccr2−/−
cancer cells. Altogether, these data support previous work
showing that the regulation of CD103+ DC infiltration is a critical
step in tumor immune surveillance (Broz et al., 2014; Meyer
et al., 2018; Roberts et al., 2016).
Figure 10. Cross-presenting CD103+ DCs are critical for immune control of Ccr2−/− cancer cells. (A) Conditioned medium from Ccr2−/− cancer cells
induces similar numbers of CD11c DCs (left) but more CD103+ BMDCs (right) in vitro compared with conditioned medium from Ccr2+/+ cancer cells (n = 3).
(B) Conditioned medium from Ccr2+/+ cancer cells cultured with CCR2 inhibitor (inh.) induced similar numbers of CD11c DCs (left) but more CD103+ BMDCs
(right) in vitro than conditioned medium from control cells cultured in the absence of the inhibitor medium (n = 3). (C) Tumors from transplanted Ccr2−/− cancer
cells have elevated Csf2mRNA (coding GM-CSF) and Flt3l (coding FLT3 ligand) but not Ccl2 or Csf3 compared with tumors from Ccr2+/+ cancer cells. RT-qPCR on
tumors from transplanted Ccr2+/+ and Ccr2−/− cancer cells during the growth-restricted phase (n = 5 or 6 for Ccr2+/+ tumors, and n = 6 for Ccr2−/− tumors).
(D) Tumor growth is increased in Batf3−/− hosts transplanted with Ccr2−/− cancer cells, as determined by weekly caliper measurements (n = 9 in Ccr2+/+ to
Batf3−/− hosts group, and n = 10 for the other three groups). (E) CD103+ DCs are increased in Ccr2−/− tumors compared with Ccr2+/+ tumors in C57BL/6 hosts
but are low in Batf3−/− hosts (n = 5). (F) CD8a+ T cells are increased in early-stage tumors (3 wk) from transplanted Ccr2−/− cancer cells compared with tumors
from Ccr2+/+ cancer cells in C57BL/6 hosts but are low in Batf3−/− hosts (n = 9 or 10). (G) Lamp-1 (CD107a) and CD8a double-positive T cells are increased in
early-stage tumors (3 wk) from transplanted Ccr2−/− cancer cells compared with tumors from Ccr2+/+ cancer cells but are low in Batf3−/− hosts (n = 9 or 10). (H)
PD-1 and CD8a double-positive T cells are increased in early-stage tumors (3 wk) from transplanted Ccr2−/− cancer cells compared with tumors from Ccr2+/+
cancer cells in C57BL/6 hosts but are low in Batf3−/− hosts (n = 5). Means ± SEM are indicated. P values were determined by Student’s t test (A–C and E–H) or
one-way ANOVA, followed by Sidak’s multiple comparisons test at the end time point (D). *, P < 0.05; **, P < 0.01; ***, P < 0.001. N.S., nonsignificant.
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Our data suggest that CCR2 signaling regulates the secretion
of a factor from the cancer cells that affects the polarization of
DCs to the CD103+ subtype. Several factors have been proposed
to induce the polarization of CD103+ DCs, including Flt3L and
GM-CSF (Mayer et al., 2014), and consistently, mRNA levels for
both of these factors were higher in tumors from Ccr2−/− cancer
cells than in those from Ccr2+/+ cancer cells. However, it is un-
clear if Flt3L and GM-CSF could be solely responsible for the
difference in CD103+ DC infiltration between tumors from
Ccr2+/+ or from Ccr2−/− cancer cells. A recent study reported that
G-CSF secreted from MMTV-PyMT cancer cells can inhibit the
differentiation of CD103+ DCs by down-regulating IFN regula-
tory factor-8 in DC progenitors (Meyer et al., 2018). Interest-
ingly, G-CSF was reduced in MMTV-PyMT;Ccr2−/− tumors
compared withMMTV-PyMT;Ccr2+/+ tumors, although secretion
of G-CSF from isolated cancer cells was not reduced, suggesting
that altered secretion is not a direct effect of CCR2 signaling in
cancer cells.
Ccr2−/− cancer cells had distinct expression of several genes,
including many that were consistent with an IFN response.
Among these, increased surface expression of MHC class I might
explain why Ccr2−/− cancer cells are more sensitive to T cell–
mediated killing than Ccr2+/+ cancer cells. However, since Ccr2+/+
cancer cells did not down-regulate MHC class I in T cell–
deficient, athymic mice, we speculate that MHC class I expres-
sion is not directly regulated by CCR2 signaling in the cancer
cells. Rather, the altered expression of IFN response genes, in-
cluding MHC class I, may be an indirect result of an immune
response in the tumors. Altogether, we propose that the cancer
cells act on CD103+ DCs, leading to a feedback loop between
CD103+ DCs and CD8+ T cells—two immune cell types with
highly interconnected functions.
Our study has several translational implications. First, our
findings provide a possible explanation as to why patients with
high CCR2 expression in breast cancer cells have a shortened
survival time compared with patients with low/negative CCR2
expression (Labovsky et al., 2017). Second, results from an open-
label nonrandomized phase I trial using a CCR2 inhibitor against
locally invasive pancreatic cancer suggest that the inhibitor
enhanced chemotherapy response, reduced macrophage infil-
tration, and induced an anti-tumor adaptive immune response
(Nywening et al., 2016). Our data suggest that the potential
clinical benefits of CCR2 inhibitors might be caused by the
combined inhibition of CCR2 signaling in both stromal and
cancer cells. Interestingly, the loss of even one Ccr2 allele was
sufficient to reduce tumor growth in our study, suggesting that
partial inhibition of CCR2 could result in clinical benefit. It is
unclear why Ccr2+/− cancer cells phenocopy the Ccr2−/− cancer
cells, but this phenomenon could be due to reduced dimerization
of CCR2 in Ccr2+/− cancer cells, consistent with a prior report
(Rodr´ıguez-Frade et al., 1999), or because surpassing a threshold
level of CCR2 signaling is required to induce immune suppres-
sion. Finally, recombinant G-CSF and GM-CSF are routinely
given with certain types of chemotherapy to support the bone
marrow and reduce the risk of lethal febrile neutropenia (Mehta
et al., 2015). Our data support prior studies suggesting that these
cytokines play complex roles in regulating the immune response
against tumors: they appear to have opposing effects on CD103+
DC differentiation, with GM-CSF stimulating CD103+ DC dif-
ferentiation (Greter et al., 2012; Mayer et al., 2014) and G-CSF
inhibiting it (Meyer et al., 2018). Although GM-CSF secretion in
the tumor microenvironment potentially enhances immune re-
sponses against tumors by stimulating CD103+ DC differen-
tiation, this cytokine can also mobilize immune-suppressive
MDSCs, leading to suppression of an anti-tumor immune re-
sponse (Bayne et al., 2012; Pylayeva-Gupta et al., 2012). Therefore,
exploring other approaches than administration of recombinant
GM-CSF and G-CSF to specifically boost CD103+ DC maturation
could be an important future translational direction, and deter-
mining the exact mechanism that causes inhibition of cancer cell
CCR2 signaling to promote CD103+ maturation may provide in-
sights into how this process occurs.
We found that tumor onset was similar between MMTV-
PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2−/− mice, while tumor
growth was slower in MMTV-PyMT;Ccr2−/− mice. These data
are very similar to a prior report studying tumor growth in
MTMV-Neumice, where mice null for Ccl2, the ligand for CCR2,
also had similar tumor onset yet reduced tumor growth rates,
as did mice treated with a CCR2 inhibitor (Chen et al., 2016b).
However, unexpectedly, MMTV-Neu mice lacking Ccr2 had
accelerated, not reduced, tumor growth in this study, and the
authors speculated that this could be due to abnormal differ-
entiation of the monocytes in these mice or unintentional ef-
fects of the genetic targeting of Ccr2. There are several possible
explanations for the difference between our result using
MMTV-PyMT;Ccr2−/− mice and that of the MMTV-Neu;Ccr2−/−
mice in the previous publication. First, tumors of MMTV-PyMT
mice have more stromal components than tumors of MMTV-
Neu mice. Second, the genetic background of the mice used in
our experiments was C57BL/6, while it was BALB/c in the case
of the MMTV-Neu model. Finally, our tumor transplantation
experiments strongly suggest that the tumor growth phenotype
in our model is caused by CCR2 expression by cancer cells, but
it is not clear whether cancer cells in the MMTV-Neu model
express CCR2 or whether the phenotype is due to effects from
stromal cells.
Despite the data suggesting that CCR2 inhibition has bene-
ficial effects in cancer treatment, some studies have raised se-
rious concerns about targeting the CCR2 ligand. Cessation of
anti-CCL2 therapy resulted in increased pulmonary metastasis
and decreased survival in amurinemodel of breast cancer due to
rapid mobilization of CCR2-expressing monocytes into the cir-
culation immediately upon cessation of therapy (Bonapace et al.,
2014). Therefore, CCR2 inhibition likely will have to be used in
combinationwith other therapies tomaximize the eradication of
existing cancer cells and to avoid complications of discontinuing
the inhibition. In summary, the divergent results across mouse
models, genetic backgrounds, and variable experimental ap-
proaches to targeting CCL2 or CCR2 suggest that the effects of
targeting this axis can depend on tumor subtype, genetic back-
ground, and cell types.
Our findings support the notion that the CCL2/CCR2 axis is
an immune modulatory pathway in cancer, but with the added
layer of complexity that cancer cells can hijack this chemokine
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receptor pathway to orchestrate immune suppression. In this
study, we focused on characterizing the cellular mechanisms
responsible for the novel link between cancer cell CCR2 signal-
ing and tumor immune suppression. Preclinical experiments
suggest that CCR2 targeting strategies can have detrimental ef-
fects, including the promotion of metastasis (Bonapace et al.,
2014; Li et al., 2013). Although we observed no effect of
anti–PD-L1 antibodies in combination with CCR2 deletion in
cancer cells, anti–PD-L1 antibodies in combination with CCR2
inhibition (which also targets CCR2 on myeloid cells) reduced
MDSC infiltration and increased survival in a mouse model of
glioma (Flores-Toro et al., 2020). Therefore, future work that
identifies the precise mechanisms by which CCR2 signaling in
cancer cells induce immune suppression in breast cancer may
set the stage for developing novel immune modulatory thera-
pies. There are ongoing clinical trials using pharmacological
inhibitors of CCR2 in cancer patients, and our data suggest that
the potential effects of inhibiting CCR2 signaling in cancer cells
should be taken into account when interpreting the results from
these trials.
Materials and methods
Mice
Ccr2−/−, Batf3−/−, and OT-1 mice (all on a C57BL/6 background)
were obtained from Jackson Laboratory, and athymic (Nu/Nu)
mice were obtained from Charles River Laboratory. MMTV-
PyMT mice (on C57BL/6 [referred to as BL/6] background)
were bred at Cold Spring Harbor Laboratory (CSHL), and
MMTV-PyMT-chOVAmice (Engelhardt et al., 2012) were a kind
gift from Dr. Mathew Krummel (University of California, San
Francisco, San Francisco, CA). MMTV-PyMT and PyMT-chOVA
mice were intercrossed with Ccr2−/− mice. MMTV-PyMT;Ccr2+/+
and MMTV-PyMT;Ccr2−/− mice, and similarly MMTV-PyMT-
chOVA;Ccr2+/+ and MMTV-PyMT-chOVA;Ccr2−/− mice, were
from the same mouse colony (mice were littermates, or their
parents were littermates). All the BL/6 host mice were pur-
chased from Jackson Laboratory. All animal experiments
were approved by the Institutional Animal Care and Use
Committee (IACUC) at CSHL and were conducted in accor-
dance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals.
Measurement of in vivo tumor growth and lung metastasis
Tumor onset was determined byweekly palpation. Once a tumor
was detected, its size was measured weekly by caliper, and tu-
mor volume was calculated as (length × width2)/2. For primary
tumor growth, mice were either sacrificed at endpoint, when
tumors reached 20 mm or ulcerated (whichever came first), or
at indicated time points (early phase: 3 wk after transplantation;
growth-restricted phase: 5–6 wk after transplantation). For the
lung metastasis assay, mice were sacrificed at either of two
IACUC-approved endpoints (when tumors reached 25 mm or
ulcerated). To determine metastatic burden, we adapted a pre-
viously published method (Nielsen et al., 2001). Briefly, lungs
were placed in 4% paraformaldehyde (PFA) in PBS in a vacuum
desiccator for 1 h. The lungs remained in 4% PFA at 4°C for 48 h,
followed by incubation in 20% sucrose in PBS at 4°C for 48 h.
Lungs were embedded in Tissue-Tek optimal cutting tempera-
ture compound embedding solution (Sakura). The blocks were
then placed in a custom-made cutting chamber with razor blade
inserts every 2 mm, and the block was cut into 2-mm sections.
These sectioned lung pieces were then reembedded in fresh
optimal cutting temperature compound to allow for cross-
sectional cuts from the entire lung tissue. These cross sections
of the lungs were stained with H&E and scanned by an Aperio
ScanScope CS System (Leica Biosystems). The metastatic burden
was calculated as the percentage of metastasis/lung area and the
number of foci/lung area, determined using Aperio eSlide Cap-
ture Devices software (Leica Biosystems). Histology was evalu-
ated by pathologist J.E. Wilkinson and scored as percentage of
solid areas of tumors.
Primary cancer cell isolation, culture, and transplantation
Aged-matched virgin females (C57BL/6, Ccr2−/−, Batf3−/−, or Nu/
Nu) 6–12 wk of age were used as hosts for transplantation.
Cancer cells were isolated from two or three tumors, each one
8–10 mm in diameter, from MMTV-PyMT;Ccr2+/+ or MMTV-
PyMT;Ccr2−/− mice. Tumors were mechanically dissociated and
digested for 1 hwith 1× collagenase/hyaluronidase (10X Solution;
Stem Cell Technology) containing DNase I (2 U/ml; Roche) in
Roswell Park Memorial Institute (RPMI)–1640 medium supple-
mented with 5% FBS (VWR Life Science Seradigm). Single cells
and debris were removed from the resulting carcinoma organoid
preparation by pulse centrifugation in HBSS supplemented with
5% FBS. Purified carcinoma organoids were dissociated into
single-cell suspension in 0.05% trypsin with 0.1% EDTA sup-
plemented with 2 U/ml of DNase I for 2–3 min. Single tumor
cells were passed through a 100-µm cell strainer (BD Bio-
sciences) and either plated in RPMI-1640 supplemented with
10% FBS for in vitro experiments or washed with PBS and im-
mediately injected into the inguinal mammary glands of host
mice (2.5 × 105 in 20 µl of 1:1 PBS/Matrigel; Corning).
To evaluate the effect of cancer cell Ccr2 on the anti-tumor
immune response locally versus systemically, contralateral trans-
plantation was conducted with cancer cells with different Ccr2
genotypes transplanted into each inguinal mammary gland
(2.5 × 105 in 20 µl of 1:1 PBS/Matrigel). Cancer cells were isolated
as described above, and both C57BL/6 and Ccr2−/−micewere used
as hosts.
To transplant irradiated cancer cells, freshly isolated primary
MMTV-PyMT;Ccr2+/+ or MMTV-PyMT;Ccr2−/− cancer cells were
plated in a 10-cm Petri dish (2 × 106 per dish) in RPMI with 10%
FBS and received 80 Gy of irradiation in the Gammacell 40
Exactor (Best Theratronics). After irradiation, cancer cells were
washed with PBS and injected into the inguinal mammary
glands of host mice (2.5 × 105 in 20 µl of PBS). To generate cancer
cell–conditionedmedium, primary cancer cells from eitherMMTV-
PyMT;Ccr2+/+ or MMTV-PyMT;Ccr2−/− tumors were plated in a
10-cm dish (2 × 106 per dish) in DMEM/F12 medium plus 10%
FBS and 1% penicillin/streptomycin, with or without CCR2
antagonist (RS504393; 10 µM; Sigma-Aldrich) for 2 d. The
conditioned medium was collected and centrifuged at 300× g
for 10 min, and the supernatant was used in experiments.
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In vivo antibody treatment
Tumor cells fromMMTV-PyMT;Ccr2+/+ or MMTV-PyMT;Ccr2−/−
mice were transplanted as described above. For anti–PD-L1
treatment, on days 15, 18, 21, and 24 after transplantation (af-
ter tumors had formed), mice received 200 µg of anti–PD-L1
antibody by intraperitoneal injection (Clone 10F.9G2; Bio X
Cell) or control rat IgG2b antibody (Bio X Cell; Winograd et al.,
2015). For CD8+ T cell depletion, mice were injected intraperi-
toneally with 200 µg of anti-CD8a antibody (Clone 2.43; BE0061;
Bio X Cell) or control rat IgG2b antibody (Clone LTF-2; BE0090;
Bio X Cell) every 3 d starting from day 0 and until day 30. Tumor
size was measured biweekly, and mice were sacrificed at the
IACUC-approved endpoint.
Flow cytometry
Tumors were harvested andmechanically dissociated for 30min
with collagenase D (2 mg/ml; Sigma-Aldrich) and DNase I (4
U/ml) in RPMI. For flow cytometry of cells from lymph nodes,
the lymph nodes were forced through a 100-µm cell strainer,
and flow-through cells were collected for experiments. Cells
were resuspended in 1 × HBSS supplemented with 0.5% BSA and
centrifuged at 300 ×g. The cell suspension was filtered through a
70-µm cell strainer, and red blood cells were lysed using red
blood cell lysing buffer (Sigma-Aldrich) for 1 min at room
temperature.
For flow cytometry staining, cells (1 × 106) were incubated
with mouse Fc Block (clone 2.4G2; BD Biosciences) for 10 min on
ice, and then stained with the appropriate antibodies to surface
markers at 4°C for 30 min in the dark or permeabilized and
stained with intracellular antibodies overnight (see below for
antibodies). Cell viability stain Zombie Red (BioLegend) was
used to differentiate between dead and live cells. The stained
populations were analyzed using an LSR II flow cytometer (BD
Biosciences; see Fig. S2 for gating strategies) and FlowJo soft-
ware (Version 10; BD Biosciences). Antibodies: CD45-eFluor 450
(Clone 30-F11), CD11c-PE-Cy7 (Clone N418), MHC II (I-A/I-
E)–APC-eFlour780 (CloneM5/114.15.2), CD103-FITC (Clone 2E7),
CD274 (B7-H1, PD-L1)–PE-Cy7 (Clone MIH5), CD3-FITC (Clone
17A2), CD8-eFluor450 (Clone 53–6.7), CD107a (LAMP-1)–PE
(Clone 1D4B), IFN-γ–PE (Clone XMG1.2), Granzyme B–FITC (Clone
NGZB), γδ TCR-PE-Cy5 (Clone GL3), and FoxP3-PE (Clone NRRF-
30) were all from eBioscience; CD4-PerCP-Cy5.5 (Clone BM9),
CD69-PE (Clone H1.2F3), F4/80-PerCP-Cy5.5 (Clone BM9), MHC I
(H-2)–PE (Clone M1/42), CD326 (EpCAM)-APC (Clone G8.8), and
CD86-BV510 (Clone GL-1) were all from BioLegend; CD45-APC
(Clone 30-F11), Ly6G-FITC (Clone 1A8), and CD11b-PE (Clone M1/
70) were from BD Biosciences; EpCAM-APC (Clone CI:A3-1) was
from AbD Serotec; and CCR2-flourescein (Clone 475301) was from
R&D Systems. Prior to Granzyme B staining, cells were incubated
for 2 h with Brefeldin A (#B6542; Sigma-Aldrich).
Cytokine array
Tumors (8–10 mm in diameter) were isolated from MMTV-
PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2−/− mice and immedi-
ately snap-frozen in liquid nitrogen. They were then ho-
mogenized in PBS with the addition of protease inhibitors
(Promega). Proteome ProfilerMouse Cytokine Array Kit, Panel A
(R&D Systems) was used according to the manufacturer’s in-
structions. Films were scanned, and spots were analyzed using
ImageJ software.
MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-
2-[4-sulfophenyl]-2H-tetrazolium) assay
Proliferation of cancer cells isolated from MMTV-PyMT;Ccr2+/+
and MMTV-PyMT;Ccr2−/− mice was measured using the Cell-
Titer 96 AQueous One Solution Cell Proliferation Assay (MTS;
Promega) according to the manufacturer’s instructions. In this
assay, the MTS tetrazolium compound (Owen’s reagent) was
bioreduced by metabolically active cells into a colored formazan
product. The quantity of formazan product was measured in a
96-well plate by absorbance at 490 nm.
RNA purification and RT-qPCR analysis
Total RNA from cancer cells (cultured 48 h in RPMI supple-
mented with 10% FBS) or primary tumors was extracted using
an RNAeasy kit (Qiagen), following the manufacturer’s in-
structions. RNA was quantified using a Nanodrop 2000 spec-
trophotometer (Thermo Fisher Scientific). Reverse transcription
was performed with an ImProm-II Reverse Transcription Sys-
tem (Promega) for the cancer cells or the RevertAid First Strand
cDNA Synthesis system (K1622; Thermo Fisher Scientific) for
the primary tumors, with the following cycling conditions:
5 min at 70°C, 10 min at 4°C, 5 min at 25°C, 60 min at 42°C, and
15 s at 70°C using 1 µg total RNA extract for 20 µl of final volume.
RT-qPCR analysis was performed using a TaqMan gene ex-
pression assay (Thermo Fisher Scientific) with the following
specific primers: Ccr2: Mm00438270_m1; Pd-l1: Mm00452054_m1;
Cd8a: Mm01182107_g1; Ifn-g: mm01168134_m1; Pd-1: mm01285676_
m1; Gzmb: mm00502528_m1; Ctla4: mm00486849_m1; Prf1:
mm00812512_m1; Clec9a: mm00554956_m1; Cxcl9: mm00434946_
m1; Cxcl10: mm00445235_m1; Cxcr3: mm00438259_m1; Cxcr4:
Mm01996749_s1; Cd11c: mm00498698_m1; Cd40: mm00441891_m1;
Cd80: mm00711660_m1;Cd86:mm00444543_m1;Ccl5: mm01302427_
m1; Il-12b: mm01288989_m1; Tim3: mm00454540_m1; Csf2:
mm01290062_m1; Flt3l: mm00442801_m1; Flt3: mm00439016_
m1; Ccl2: mm00441242_m1; Csf3: mm00438334_m1; Csf1:
mm00432686_m1; and Tbp: mm01277042_m1.
For cancer cells, RT-qPCR was performed on three indepen-
dently isolated cancer cell populations and in triplicate for each
sample. To determine the effects of IFN-γ on Pd-l1 expression,
cancer cells were cultured with the indicated concentration of
IFN-γ (#485-MI-100; R&D Systems) for 48 h before isolation of
RNA. For tumor samples, RT-qPCR was performed on at least
five primary tumors from different mice and in triplicate for
each sample. Relative quantitation was performed with the
2(−ΔΔCT) method using β-Actin or Tbp expression for normaliza-
tion andMMTV-PyMT;Ccr2+/+ cancer cells or tumor samples as a
reference sample.
RNA in situ hybridization (ISH)
RNA ISHwas performed on PFA-fixed paraffin-embedded tissue
sections using an RNAscope Chromogenic 2.0 Detection Kit
(Advanced Cell Diagnostics [ACD], Inc.). A Ccr2 probe was cus-
tom designed by ACD, Inc. (#436261-C2) and used according to
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the manufacturer’s instructions. We confirmed that no signal
was found with the probe using Ccr2−/− tissues. RNA FISH for
Ccr2, Krt8, Cd8a, and Ifn-g was performed on fresh frozen tissue
sections using an RNAscope Fluorescent Multiplex Assay Kit
(ACD, Inc.) with the following probes (by ACD, Inc.): Ccr2:
436261-C2; Krt18: 424531-C1; Cd8a: 401681-C1; and Ifn-g: 311391-
C3. They were used according to the manufacturer’s instructions.
For Ccr2 RNA FISH, we confirmed that no signal was found with
the probe using Ccr2−/− tissues.
H&E staining
PFA-fixed paraffin-embedded tissue sections were deparaffinized
and rehydrated following standard protocols, stained with Gill’s
Hematoxylin (REF6765008; Thermo Fisher Scientific) for 3 min,
washed in tapwater, rinsedwithNu-Clear II (REF6769009; Thermo
Fisher Scientific), and then rinsed again first with tap water and
then with Bluing Reagent (REF 6769001; Thermo Fisher Scientific).
Slides were then stained with eosin (HT110180; Sigma-Aldrich),
dehydrated following standard protocols, air-dried, and mounted
with Cytoseal 60 (#831016; Thermo Fisher Scientific).
Immunofluorescence staining
To stain for cytokeratin 5 and cytokeratin 8, paraffin sections
were deparaffinized and rehydrated, and antigen retrieval was
performed by boiling slides in Tris EDTA buffer (10 mM Tris
base and 1 mM EDTA, pH 9.0) for 6 min in a pressure cooker.
The slides were blocked with 1× blocking buffer (PBS containing
2.5% BSA and 5% goat serum) and Fc receptor blocker (In-
novex Biosciences) before incubating with anti–cytokeratin
5–Alexa Fluor 488 conjugated antibody (ab193894; 1:200 di-
lution; Abcam) and anti-Cytokeratin 8-Alexa Fluor 405 con-
jugated antibody (ab210139; 1:200 dilution; Abcam) overnight
at 4°C. Sections were counterstained with ToPro-3 (1:1,000
dilution; Life Technologies).
For all other stainings, frozen tissue sections were incubated
with 1x blocking buffer (5% goat serum and 2.5% BSA in PBS)
and Fc receptor blocker. Sections were incubated with rabbit
anti-CD3 polyclonal antibody (1:500 dilution; Abcam), rat anti–
MHC class I monoclonal antibody (Clone ER-HR52, 1:100 dilu-
tion; Abcam), rat anti-PyMT antibody (Ab15085, 1:200 dilution;
Abcam), rabbit anti-cleaved caspase-3 (Asp175; D3E9; #9579;
1:200 dilution; Cell Signaling Technology), anti–CD8a–Alexa Fluor
488 (Clone 5.3–6.7), anti–CD11c–Alexa Fluor 488 (Clone N418), or
anti–CD326 (EpCAM)-APC (Clone G8.8) in 0.5× blocking buffer
overnight at 4°C. Secondary antibodies (not used for primary
antibodies conjugated to Alexa Fluor 488) anti–rabbit-Alexa568 or
anti–rat-Alexa568 (1:150 dilution; Life Technologies) were used for
detection, and sections were counterstained with DAPI (1:200
dilution; Life Technologies). Images were collected at 40× mag-
nification using a Leica SP8 confocal or an AX10 microscope and
an AxioCamHRc camera (Zeiss) andwere analyzed using Volocity
software (Version 6.3.0; PerkinElmer).
Immunohistochemistry and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining
Sections were deparaffinized and rehydrated. For phospho-
STAT3 and Ki67 staining, antigen retrieval was performed by
boiling slides in 10 mM sodium citrate buffer (pH 6.0) for 6 min
in a pressure cooker, while for phospho-STAT1 staining, an-
tigen retrieval was done in Tris EDTA buffer (10 mM Tris base
and 1 mM EDTA, pH 9.0). The slides were blocked with 3%
hydrogen peroxide, 1× blocking buffer (PBS containing 2.5%
BSA and 5% goat serum), Fc receptor blocker, and finally av-
idin/biotin blocking buffer (SP-2001; Vector Laboratories).
Slides were then incubated with primary antibodies overnight
at 4°C in 0.5× blocking buffer: rabbit anti–Ki67/MK167 (1:
1,000 dilution; NB110-89717; Novus International), rabbit
anti–phospho-STAT1 (1:200 dilution; Cell Signaling Technology),
or rabbit anti–phospho-STAT3 (1:500 dilution; Cell Signaling
Technology). After incubating with secondary biotinylated goat
anti-rabbit IgG antibody (1:500 dilution; BA-1000; Vector Labo-
ratories) for 1 h at room temperature, slides were incubated with
avidin-conjugated horseradish peroxidase (PK-6100; Vector
Laboratories) for 30 min, and the signals were detected by a 3,39-
diaminobenzidine substrate kit (SK-4100; Vector Laboratories).
Lastly, sections were counterstained with hematoxylin. TUNEL
staining was performed on deparaffinized sections to detect
late-stage apoptotic cells using the ApopTag peroxidase in situ
apoptosis detection kit (Millipore) according to the manu-
facturer’s instructions. Images were scanned by an Aperio
ScanScope CS System (Leica Biosystems), and positive nuclei
were counted using Aperio eSlide Capture Devices software
(Leica Biosystems).
ImmunoSEQ
Tumors from Ccr2+/+ and Ccr2−/− transplants were isolated and
immediately placed in liquid nitrogen for shipment. Amplifica-
tion and sequencing were performed on the immunoSEQ plat-
form (Adaptive Biotechnologies) using a multiplex PCR-based
assay that exclusively targets rearranged TCR genes. Sequencing
data were analyzed using immunoSEQ Analyzer software. Shan-
non’s Entropy (H), a measure of the richness and uniformity of
the frequency of the TCR repertoire distribution, was defined as
follows:
H  −
XN
i1
Pilog2Pi,
where N equals the number of unique clones and Pi the fre-
quency of clones. To account for variation in sequencing depth,
entropy was normalized by its maximum value (Hmax):
HN  H/Hmax.
Clonality is defined as C = 1 − HN (Sherwood et al., 2013). Se-
quencing files are available from the immunoSEQ website
through accession DOI 10.21417/MF2020JEM.
Transcriptional profiling and bioinformatics analysis
Ccr2+/+ or Ccr2−/− cancer cells were isolated from tumors and
sorted as EpCAM+CD45−CD31− live cells (using 7-AAD Viability
Staining Solution; Thermo Fisher Scientific) 4 wk after ortho-
topic transplantation into the mammary glands of wild-type
C57BL/6 mice. Total cancer cell RNA was extracted using a
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TRIzol extraction protocol. cDNA libraries were prepared using
the Ovation RNA-Seq System V2 (NuGEN Technologies) ac-
cording to the manufacturer’s protocol and sequenced using a
NextSeq 500 instrument (Illumina) to obtain 388 million 76-bp
single-end reads. Reads were mapped to the reference mm9
mouse genome using Spliced Transcripts Alignment to a Ref-
erence (Dobin et al., 2013) and were determined using HTSeq
(Anders et al., 2015). Differential gene expression analysis was
performed using DESeq2 (Love et al., 2014) with a false dis-
covery rate cutoff of 5%. Hierarchical clustering was performed
by sample and gene using normalized and log2-transformed
gene expression values of differentially expressed genes. All of
the analyses described abovewere performed on the Bioinformatics
Shared Resource Galaxy server at CSHL. Gene set enrichment
analysis (Subramanian et al., 2005) was performed on a pre-
ranked gene list sorted by log2FoldChange value against v5.1
Hallmark gene sets using default parameters. GO term enrich-
ment analysis was performed using GOrilla PANTHER (Eden
et al., 2009). The RNA-seq data have been deposited in the Se-
quence Read Archive with accession no. PRJNA605445 (https://
www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA605445).
BMDC isolation, culture, and activation
BMDCs were isolated and cultured as previously described
(Inaba et al., 1992). Briefly, bone marrow was obtained from
female C57BL/6 mice by flushing the femur and tibia with 2 ml
of HBSS using a 1-ml insulin syringewith a 29G × 1/2 needle. The
cells were washed with HBSS twice by centrifugation at 250 ×g
for 8 min and then suspended in BMDC culture medium (RPMI-
1640 medium [Thermo Fisher Scientific] containing 10% FBS,
20 ng/ml recombinant mouse GM-CSF [BioLegend], 50 U/ml
penicillin, and 50 µg/ml streptomycin). The cells were then
plated in 10-cm culture plates (2 × 106 cells per Petri dish) and
kept at 37°C in a 5% CO2 incubator for 3 d, and then split at day
4 into two plates. For activation of BMDCs with cancer cell–
conditioned medium, the nonattached BMDCs were harvested
at day 6 by gently pipetting the cultures with medium. This
BMDC population was then rinsed three times in HBSS and
suspended in (1) culture medium, (2) conditioned medium
fromMMTV-PyMT;Ccr2−/− or MMTV-PyMT;Ccr2+/+ cancer cells,
or (3) conditioned medium from MMTV-PyMT;Ccr2+/+ cancer
cells cultured either with or without CCR2 antagonist (10 µM;
RS504393; Sigma-Aldrich). After incubation with conditioned
medium for 24 h, nonadherent BMDCs were harvested for flow
cytometry.
Chromium release assay
Cytotoxic CD8+ T cells were isolated from spleens of OT-I
transgenic mice by magnetic labeling and separation (Miltenyi
Biotec). Briefly, the spleen was forced through a 100-µm cell
strainer, and flow-through cells were collected. After red blood
cells were lysed, the splenocytes were washed and incubated
with CD8a+ T Cell Biotin-Antibody Cocktail, mouse (Miltenyi
Biotec) at 4°C for 5 min, followed by incubating with anti-biotin
microbeads (Miltenyi Biotec) at 4°C for 10 min. The cell sus-
pension was applied to an LS column (Miltenyi Biotec) in a
magnetic field, and the flow-through (negatively selected) CD8+
T cells were collected. The isolated CD8+ T cells were cultured on
plates coated with anti–mouse-CD3 (BioLegend) in RPMI-1640
containing 10% FBS, 50 µM of β-mercaptoethanol, 20 ng/ml
mouse IL-2, 2 ng/ml mouse IL-7, and 1% penicillin/streptomycin
for 6–9 d. Primary cancer cells were isolated as described above
from MMTV-PyMT-chOVA;Ccr2+/+ or MMTV-PyMT-chOVA;
Ccr2−/− mice and cultured overnight with or without CCR2 an-
tagonist (10 µM; RS504393) and OVA peptides (1 µg/ml) in
DMEM/F12 medium with 10% FBS. The E0771 cancer cell line
was infected with lentivirus expressing luciferase and OVA
SIINFEKL peptide fused to the C-terminus of enhanced GFP.
Transduced cells were sorted by flow cytometry for enhanced
GFP–positive cells. For chromium (51Cr) release assay, cancer
cells (1,000 per well) were incubated with 50 µl of 51Cr solution
(activity 1 mCi/ml; PerkinElmer) plus 50 µl of RPMI medium
with 10% FBS for 2 h at 37°C. After the cells were rinsed three
times with RPMI plus 10% FBS, 50 µl of cancer cells (1,000)
were plated into each well of a 96-well V-bottom plate, followed
by the addition of 50 µl of CD8+ T cells at a ratio of 10:1. After 4 h
of incubation at 37°C, 50 µl of supernatant from each well was
transferred to miniature vials, and radioactivity was determined
by a Beckman scintillation counter (PerkinElmer). The percentage
of specific lysis was calculated using the standard formula [(ex-
perimental − spontaneous release)/(total − spontaneous release) ×
100] and expressed as the mean of triplicate samples.
Western blot
Snap-frozen tumor samples were homogenized in radio immu-
noprecipitation assay buffer with cOmplete Protease Inhibitor
Cocktail Tablets (Roche) and phosphatase inhibitor cocktail
(Thermo Fisher Scientific), and lysis was performed on ice for
30 min. Cell lysates were centrifuged for 15 min at 12,000 ×g at
4°C. After centrifugation, the supernatant was mixed with 4×
loading buffer plus 2.5% of β-mercaptoethanol and loaded on 8%
SDS/PAGE gels. Proteins with similar molecular weight were
detected using blots from separate gels loaded with an equal
amount of samples. Protein bands were transferred to poly-
vinylidene difluoride membranes (Bio-Rad) at 90 V for 2 h in a
Bio-Rad Mini Trans-Blot system. The membrane was incubated
sequentially with different primary antibodies: anti-p65, anti–
p-p65, anti–p-STAT1, anti–p-STAT3, and anti-STAT3 (all from
Cell Signaling Technology) and anti-STAT1 and anti–β-Actin
(Santa Cruz Biotechnology). Secondary antibodies were from
LI-COR. Protein detection was performed using the Odyssey
imaging system (LI-COR).
Whole-mount carmine staining of mammary glands
Mammary glands were isolated and spread out on glass slides.
Then, the mammary glands were fixed in Carnoy’s fixative (60%
ethanol, 30% chloroform, and 10% glacial acetic acid) for 2–4 h at
room temperature, followed by 15-min washes first in 70% and
then in 50% ethanol, with a final rinse in double-distilled water.
The glands were then stained with carmine red stain (2.5 g of
aluminum potassium sulfate, 1 g of carmine, and dH2O to a final
volume of 500 ml, and boiled for 25 min) for 16 h or until the fat
pad was a uniform pink color. After staining, the mammary
glands were de-stained in 1% solution of 1N HCl in 70% ethanol.
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De-stained glands were rinsed twice for 15 min in 70% ethanol
followed by 15-min washes first in 90% and then in 100% eth-
anol. The mammary glands were then placed in xylene for 2 h
for clearing and were mounted.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
Version 6 or newer software. Data were analyzed using Kaplan-
Meier survival analysis, Student’s t tests, ANOVA, χ2 test,
and log-rank (Mantel-Cox) test, as indicated in the figure
legends, with an α of 0.05. For tumor volume analysis, one-
way ANOVA followed by Sidak’s multiple comparisons test;
Welch’s ANOVA followed by Dunnett’s T3 multiple com-
parisons test; or Student’s t tests were performed as indi-
cated in the legends. The number of sampled units, n, is indicated
in the figure legends.
Online supplemental material
Fig. S1 (related to Fig. 1) shows CCR2 expression in spontaneous
MMTV-PyMT tumors and lungs. Fig. S2 shows the flow cy-
tometry gating strategy for immune cells. Fig. S3 (related to Figs.
4 and 5) shows T cell infiltration and depletion in tumors derived
from Ccr2+/+ or Ccr2−/− cancer cells. Fig. S4 (related to Figs. 8 and
9) shows the activation of T cells and the infiltration of myeloid
cell in tumors derived from Ccr2+/+ or Ccr2−/− cancer cells. Fig. S5
(related to Fig. 10) shows cytokine analysis in tumor lysate and
conditioned medium.
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Figure S1. CCR2 expression in spontaneous MMTV-PyMT tumors and lungs. (A) Mammary ductal epithelial branching and invasion are similar in Ccr2+/+
and Ccr2−/−mice, as indicated by carmine red staining of inguinal mammary glands at indicated age (left; scale bar = 4 mm) and immunofluorescence staining of
basal and luminal cell markers (right; cytokeratin [CK] 5 and CK8, respectively; scale bar = 100 µm). (B) Representative photomicrographs of H&E–stained
tumors fromMMTV-PyMT;Ccr2+/+, MMTV-PyMT;Ccr2+/−, and MMTV-PyMT;Ccr2−/−mice (scale bar = 1 mm). (C) Histology score of solid area of primary tumors
from MMTV-PyMT;Ccr2+/+, MMTV-PyMT;Ccr2+/−, and MMTV-PyMT;Ccr2−/− mice (one-way ANOVA; n = 8 in MMTV-PyMT;Ccr2+/+, n = 11 in MMTV-PyMT;
Ccr2+/−, and n = 12 in MMTV-PyMT;Ccr2−/−). (D) Left: Representative RNA FISH on MMTV-PyMT;Ccr2+/+ tumors showing that Ccr2mRNA (green) is expressed
by Krt18-positive (red) cancer cells. Right: No Ccr2 expression is detected in MMTV-PyMT;Ccr2−/− tumors. Scale bar = 20 µm. (E) Purity of cancer cells is >90%
after cell isolation, as determined by flow cytometry for EpCAM (black; a marker expressed on epithelial-derived MMTV-PyMT cells) compared with back-
ground (gray). Representative of three separate isolations. (F)mRNA was collected fromMMTV-PyMT;Ccr2+/+, MMTV-PyMT;Ccr2+/−, and MMTV-PyMT;Ccr2−/−
tumor cells, and qPCR was performed for Ccr2 and normalized to β-actin expression (one-way ANOVA; n = 3). (G) Tumors from Ccr2+/− cancer cells phenocopy
those from Ccr2−/− cancer cells, regardless of whether the host is Ccr2+/+ or Ccr2−/−. Tumor burden was determined by weekly caliper measurements (one-way
ANOVA followed by Sidak’s multiple comparisons test at the end time point; n = 8 for all conditions). (H) Metastatic burden is unchanged in MMTV-PyMT;
Ccr2+/+, MMTV-PyMT;Ccr2+/−, and MMTV-PyMT;Ccr2−/− mice, as determined by quantification from H&E–stained lung sections, indicated as percentage of the
area of the lung tissues (one-way ANOVA; n = 24 MMTV-PyMT;Ccr2+/+, 33 MMTV-PyMT;Ccr2+/−, and 27 MMTV-PyMT;Ccr2−/− mice). (I) The number of
metastatic foci is unchanged inMMTV-PyMT;Ccr2+/+, MMTV-PyMT;Ccr2+/−, and MMTV-PyMT;Ccr2−/−mice. Mice were classified as having either ≤ or > 0.1 foci/
mm2 lung area (χ2 test; n = 24 MMTV-PyMT;Ccr2+/+, 33 MMTV-PyMT;Ccr2+/−, and 27 MMTV-PyMT;Ccr2−/− mice). (J) The average size of the metastatic foci is
decreased in MMTV-PyMT;Ccr2+/− and MMTV-PyMT;Ccr2−/− mice compared with foci in MMTV-PyMT;Ccr2+/+ mice. The number of mice with an average of
large versus small metastatic foci is indicated (χ2 test; n = 24 MMTV-PyMT;Ccr2+/+, 33 MMTV-PyMT;Ccr2+/−, and 27 MMTV-PyMT;Ccr2−/− mice). Means ± SEM
are indicated. P values were determined by the tests indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001. N.S., nonsignificant.
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Figure S2. Gating strategy for immune cells. For flow cytometry analysis, single cells from tumors were gated on live CD45+ cells and were further analyzed
using the indicated markers to characterize infiltration of tumor-associated macrophages (TAMs), DCs, T cells, granulocytes, monocytes, and MDSCs. SSC, side
scatter; gMDSC, granulocytic myeloid-derived suppressor cell; mMDSC, monocytic myeloid-derived suppressor cell.
Fein et al. Journal of Experimental Medicine S3
CCR2 signaling in cancer cells causes immune evasion https://doi.org/10.1084/jem.20181551
D
ow
nloaded from
 http://rupress.org/jem
/article-pdf/217/10/e20181551/1047390/jem
_20181551.pdf by C
old Spring H
arbor Laboratory user on 12 August 2020
Figure S3. T cell infiltration in tumors derived from Ccr2+/+ or Ccr2−/− cancer cells. (A) There is no difference between Ccr2+/+ and Ccr2−/− tumors during
the growth-restricted phase in the percentage of CD3+ T cells among CD45+ leukocytes, as determined by flow cytometry for CD45+CD3+ cells (n = 5).
(B) FoxP3+CD4+ regulatory T cell infiltration is increased in Ccr2+/+ tumors compared with Ccr2−/− tumors during the growth-restricted phase, as determined by
flow cytometry gated on CD45+CD3+CD4+ cells (n = 5). (C) Depletion of CD8+ T cells with anti-CD8a antibody significantly accelerated the growth of tumors
from Ccr2−/− cancer cells (arrows indicate treatment with antibody; n = 5 for all conditions). (D) Pharmacological inhibition of CCR2 increased OT-1 T cell
cytotoxicity toward E0771 cancer cells expressing OVA peptide, as measured by chromium (Cr51) release (each dot is a triplicate from the same experiment, and
similar results were obtained in an independently performed experiment). (E) Immune suppression induced by cancer cell CCR2 signaling is confined to the
local tumor microenvironment. Ccr2+/+ cancer cells transplanted into one mammary gland did not alter the growth of tumors from Ccr2−/− cancer cells
transplanted to the contralateral gland. Means ± SEM are indicated. P values were determined by Student’s t test (A, B, and D). Tumor burden was determined
by weekly caliper measurements (n = 10 for all conditions). Tumor volume was analyzed at the end time point by one-way ANOVA, followed by Sidak’s multiple
comparisons test (C) or by Welch’s ANOVA followed by Dunnett’s T3 multiple comparisons test (due to unequal variances; E). *, P < 0.05; **, P < 0.01. N.S.,
nonsignificant.
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Figure S4. Myeloid cell infiltration in tumors derived from Ccr2+/+ or Ccr2−/− cancer cells. (A) Tumors from transplanted Ccr2−/− cancer cells have el-
evated markers of T cell infiltration and activation, including Cd8, Ifn-g, and Cxcl9 mRNA, compared with tumors from Ccr2+/+ cancer cells. RT-qPCR was
performed on tumors from transplants of Ccr2+/+ and Ccr2−/− cancer cells isolated during the growth-restricted phase (n = 5 or 6 for Ccr2+/+ tumors, and n = 6–8
for Ccr2−/− tumors). (B) Representative RNA FISH for Ifn-g (green) and Cd8a (red) probes in the early phase (3 wk; upper panels) and the late, growth-restricted
phase (5–6 wk; bottom panels) of tumors from Ccr2+/+ and Ccr2−/− transplanted cancer cells. Nuclei are counterstained with DAPI (blue; scale bar = 20 µm).
(C and D) Quantification of RNA FISH shows more Ifn-g–expressing Cd8+ T cells in tumors from Ccr2−/− cancer cells compared with Ccr2+/+ cancer cells at both
early (C) and late, growth-restricted (D) phases (each dot represents the average of three to eight random fields of views of one tumor; n = 5 tumors for early
phase; n = 7 or 8 tumors for late, growth-restricted phase). (E) Macrophage infiltration is unchanged between Ccr2+/+ and Ccr2−/− tumors during the growth-
restricted phase, as determined by flow cytometry gated on CD45+CD11b+MHC class II+ F4/80+ cells (n = 5 and 4 for Ccr2+/+ and Ccr2−/− tumors, respectively).
(F) Percentage of CD11b+MHC class II− cells is reduced in Ccr2−/− tumors compared with Ccr2+/+ tumors during the growth-restricted phase, as determined by
flow cytometry gated on CD45+ cells (n = 5 and 4 for Ccr2+/+ and Ccr2−/− tumors, respectively). (G) Granulocytes and granulocytic MDSCs are decreased on
Ccr2−/− tumors during the growth-restricted phase, as determined by flow cytometry gated on CD45+CD11b+CD11c−Ly6G+Ly6C+ cells (n = 5). (H) Inflammatory
monocytes and monocytic MDSCs are increased on Ccr2−/− tumors during the growth-restricted phase, as determined by flow cytometry gated on
CD45+CD11b+CD11c−Ly6G−Ly6C+ cells (n = 5). (I) CD103+ DCs are increased in MMTV-PyMT;Ccr2−/− tumors compared with MMTV-PyMT;Ccr2+/+ tumors during
the growth-restricted phase, as determined by flow cytometry gated on CD11c+MHCII+ cells within the CD45+ population (n = 4 and 5 for MMTV-PyMT;Ccr2+/+
and MMTV-PyMT;Ccr2−/− tumors, respectively). Means ± SEM are indicated. P values were determined by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P <
0.001. N.S., nonsignificant.
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Figure S5. Cytokine analysis in tumor lysate and conditioned medium. (A) Cytokine analysis from MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2−/− tumors
during growth-restricted phase, using the Proteome Profiler Mouse Cytokine Array Kit, Panel A (n = 4). (B) Cytokine analysis from supernatant of MMTV-PyMT;
Ccr2+/+ and MMTV-PyMT;Ccr2−/− cancer cells isolated during growth-restricted phase, using the Proteome Profiler Mouse Cytokine Array Kit, Panel A after
serum starvation for 24 h (n = 4). Means ± SEM are indicated. P values were determined by multiple Student’s t tests. *, P < 0.05.
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